TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31073654

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) measurements pre- and post-puncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: PDPH-free patients' TCD measurements
Number of subjects: 90
Study: 31073959

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard three-port laparoscopic cholecystectomy (LC)
Number of subjects: 185
Study: 31074004

Group type: EXPERIMENTAL
Intervention: Faecal gluten peptides testing
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tissue transglutaminase antibody levels
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dietitian assessment
Number of subjects: 64
Study: 31074220

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 31075167

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB) scale
Number of subjects: 402

Group type: COMPARATOR
Intervention: Baseline characteristics, GRACE, and TIMI risk scores
Number of subjects: 402
Study: 31075217

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) imaging
Number of subjects: 15
Study: 31075309

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 31075618

Group type: EXPERIMENTAL
Intervention: MR-proANP
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PCT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 42
Study: 31075727

Group type: EXPERIMENTAL
Intervention: Dose-dense epirubicin, paclitaxel and cyclophosphamide (EPC)
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Dose-dense epirubicin, cyclophosphamide, paclitaxel and capecitabine (EC-PwX)
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: PD-1-positive immune cells in TNBC
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: PD-L1 expression
Number of subjects: 1318
Study: 31075769

Group type: EXPERIMENTAL
Intervention: Cervical disc arthroplasty (CDA)
Number of subjects: 0
Study: 31075771

Group type: EXPERIMENTAL
Intervention: Visible 5-ALA fluorescence
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Quantitative PpIX analysis
Number of subjects: 22
Study: 31076139

Group type: EXPERIMENTAL
Intervention: Echocardiography measurements by seven sonographers (n = 350 echocardiograms measured)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Echocardiographic acquisition by four sonographers (n = 176 acquisitions and measures)
Number of subjects: 25000
Study: 31076409

Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 10 mg daily starting on day 9 of cycle 1 and IV rituximab 375 mg/m2
Number of subjects: 0
Study: 31076416

Group type: EXPERIMENTAL
Intervention: Prediabetes (IGT or IFG) after revascularization, optimal medical therapy, or both
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal glycemic status
Number of subjects: 101
Study: 31076448

Group type: EXPERIMENTAL
Intervention: CD8 T-cells from CLL patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control CD8 T-cells (not specified if from healthy individuals or other sources)
Number of subjects: 0
Study: 31076474

Group type: EXPERIMENTAL
Intervention: Resuscitative endovascular balloon occlusion of the aorta (REBOA) procedure
Number of subjects: 10
Study: 31076762

Group type: EXPERIMENTAL
Intervention: Stereotactic laser ablation (SLA)
Number of subjects: 100
Study: 31077039

Group type: EXPERIMENTAL
Intervention: High-dose α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination
Number of subjects: 13
Study: 31077164

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with platinum-doublet chemotherapy
Number of subjects: 987
Study: 31077265

Group type: EXPERIMENTAL
Intervention: Interleukin 10 (IL-10) measured in serum samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin 10 (IL-10)
Number of subjects: 0
Study: 31077529

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (continuous subcutaneous insulin infusion for 7 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (nondiabetics)
Number of subjects: 21
Study: 31077579

Group type: EXPERIMENTAL
Intervention: NAVA levels increasing (0.5 to 4.0 cmH2O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NAVA levels decreasing
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NAVA (general)
Number of subjects: 14
Study: 31077699

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD) for pEGC
Number of subjects: 121

Group type: COMPARATOR
Intervention: Endoscopic submucosal dissection (ESD) for pEGC outside criteria
Number of subjects: 121
Study: 31077821

Group type: EXPERIMENTAL
Intervention: HLE present at day 0
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Factor VIII activity >160%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Level of protein C <34%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Antithrombin activity <28%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: International normalized ratio >2.6
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Factor VIII activity
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: International normalized ratio
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Level of protein C
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Model for end-stage liver disease score
Number of subjects: 78
Study: 31077981

Group type: EXPERIMENTAL
Intervention: Late-life depression (LLD)
Number of subjects: 44
Study: 31078447

Group type: EXPERIMENTAL
Intervention: Evidence-based prototype of a discharge report for the community pharmacist
Number of subjects: 19
Study: 31078468

Group type: EXPERIMENTAL
Intervention: Survivors of acute lymphoblastic leukaemia
Number of subjects: 980

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Survivors treated on protocols between 1962-91
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Survivors treated on protocols between 1991-2007
Number of subjects: 980
Study: 31078541

Group type: EXPERIMENTAL
Intervention: Presence of Neovascularization of the Disc (NVD)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ischemic Index (ISI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Neovascularization Elsewhere (NVE)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Presence of NVE in the posterior polar retina
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall global ischemia
Number of subjects: 38
Study: 31079357

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg qd for 12 weeks
Number of subjects: 0
Study: 31080027

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 2492

Group type: COMPARATOR
Intervention: Outpatient management (discharged patients)
Number of subjects: 2492

Group type: EXPERIMENTAL
Intervention: Hospitalization (after propensity score matching)
Number of subjects: 2492

Group type: COMPARATOR
Intervention: Outpatient management (discharged patients after propensity score matching)
Number of subjects: 2492
Study: 31080494

Group type: EXPERIMENTAL
Intervention: INET (intra-neuroendoscopic technique)
Number of subjects: 98

Group type: COMPARATOR
Intervention: CPDO (cranial puncture and drainage operation)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: INET
Number of subjects: 98
Study: 31080608

Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 299

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 299
Study: 31080731

Group type: EXPERIMENTAL
Intervention: Motor Control Exercise (MCE) plus Patient Education (PE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Motor Control Exercise (MCE)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patient Education (PE)
Number of subjects: 120
Study: 31080813

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 40
Study: 31081020

Group type: EXPERIMENTAL
Intervention: 8-hourly lopinavir/ritonavir dosing strategy
Number of subjects: 11
Study: 31081589

Group type: EXPERIMENTAL
Intervention: Sodium glucose cotransporter type 2 inhibitors (SGLT-2i)
Number of subjects: 0
Study: 31082360

Group type: EXPERIMENTAL
Intervention: FET procedure with debranch-first technique
Number of subjects: 34
Study: 31082392

Group type: EXPERIMENTAL
Intervention: Magnetically assisted capsule endoscopy (MACE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 33
Study: 31082539

Group type: EXPERIMENTAL
Intervention: S-ICD
Number of subjects: 1116
Study: 31082665

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 31082688

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) with or without chemotherapy
Number of subjects: 36
Study: 31083725

Group type: COMPARATOR
Intervention: Updated Diamond-Forrester (UDF) model
Number of subjects: 1675

Group type: COMPARATOR
Intervention: CAD Consortium Basic model
Number of subjects: 1675

Group type: COMPARATOR
Intervention: CAD Consortium Clinical model
Number of subjects: 1675

Group type: COMPARATOR
Intervention: CAD Consortium Clinical + CACS model
Number of subjects: 1675

Group type: COMPARATOR
Intervention: UDF model
Number of subjects: 1675
Study: 31084325

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 24040

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 24040

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 24040

Group type: COMPARATOR
Intervention: Aspirin, Warfarin, DOAC
Number of subjects: 24040
Study: 31084335

Group type: EXPERIMENTAL
Intervention: Surpass Flow Diverter
Number of subjects: 180
Study: 31084544

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Cytoreductive surgery alone (CRSa)
Number of subjects: 277
Study: 31084924

Group type: EXPERIMENTAL
Intervention: Measured GFR using iohexol clearance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Estimated GFR using creatinine and cystatin C in MDRD or CKD-EPI equations
Number of subjects: 20
Study: 31084936

Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers with immediate dentin sealing (IDS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceramic laminate veneers without immediate dentin sealing (IDS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceramic laminate veneers on teeth with pre-existing resin composite restorations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers on teeth without pre-existing resin composite restorations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ceramic laminate veneers on vital teeth
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceramic laminate veneers on non-vital teeth
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ceramic laminate veneers on endodontically-treated teeth
Number of subjects: 104

Group type: COMPARATOR
Intervention: Patients who smoked
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 104
Study: 31085321

Group type: EXPERIMENTAL
Intervention: Monophasic PFA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Biphasic PFA
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both monophasic and biphasic PFA
Number of subjects: 81
Study: 31085605

Group type: EXPERIMENTAL
Intervention: iReadMore therapy (a therapy app for reading training)
Number of subjects: 0
Study: 31085677

Group type: EXPERIMENTAL
Intervention: BabyLux device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulse oximeter
Number of subjects: 30
Study: 31085763

Group type: EXPERIMENTAL
Intervention: Combination BRAF and MEK inhibition
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Cabozantinib therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Detection of KRAS G12V mutation
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Peripheral blood samples
Number of subjects: 1
Study: 31085817

Group type: EXPERIMENTAL
Intervention: Breath VOC MAGIIC biomarker
Number of subjects: 301
Study: 31085945

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) flow cytometry analysis in patients with postoperative cognitive dysfunction.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) flow cytometry analysis in matched controls without postoperative cognitive dysfunction.
Number of subjects: 10
Study: 31086307

Group type: EXPERIMENTAL
Intervention: 160 L alglucosidase alfa
Number of subjects: 113
Study: 31087226

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 31087382

Group type: EXPERIMENTAL
Intervention: HBsAg vaccine (Engerix-B) as challenge dose
Number of subjects: 0
Study: 31087388

Group type: EXPERIMENTAL
Intervention: Class 1 (n = 28 [14.7%])
Number of subjects: 221

Group type: COMPARATOR
Intervention: Class 2 (n = 162 [85.3%])
Number of subjects: 221
Study: 31087457

Group type: EXPERIMENTAL
Intervention: Class I defect (infraosseous)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Class II defect (horizontal)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Class III defect (combined)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Severity M (moderate)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Severity S (slight)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Buccal bone loss
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Smoking habit
Number of subjects: 47
Study: 31087772

Group type: EXPERIMENTAL
Intervention: Locoregional therapies (LRT)
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: One single LRT
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: 2-3 LRTs
Number of subjects: 2019

Group type: EXPERIMENTAL
Intervention: ≥4 LRTs
Number of subjects: 2019

Group type: COMPARATOR
Intervention: LRTs (up to 3)
Number of subjects: 2019
Study: 31088152

Group type: EXPERIMENTAL
Intervention: PAH-C
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PAH-D
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 80
Study: 31088520

Group type: EXPERIMENTAL
Intervention: Automatically activated network of trained volunteers via smartwatch and smartphone applications (Intervention Group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Emergency health services only (Control Group)
Number of subjects: 134
Study: 31088560

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity level (PAL)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Physical activity measured by YPAS
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Respiratory symptoms assessment
Number of subjects: 2190
Study: 31088809

Group type: EXPERIMENTAL
Intervention: Acalabrutinib 100 mg twice daily or 200 mg once daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 33
Study: 31088831

Group type: EXPERIMENTAL
Intervention: Erdafitinib (oral pan-FGFR inhibitor)
Number of subjects: 187
Study: 31089278

Group type: EXPERIMENTAL
Intervention: Bu-Oral (oral busulfan)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bu-IV (intravenous busulfan)
Number of subjects: 40
Study: 31089682

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4033

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (quartile of largest weight loss after 1 year)
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (after adjustment for confounders)
Number of subjects: 4033
Study: 31089689

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplement (1.0 μmol [14,15]-13C2-retinyl acetate)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Routine 200,000 IU vitamin A capsule administered after RID test
Number of subjects: 94

Group type: COMPARATOR
Intervention: Consumption of liver ≥1/month
Number of subjects: 94

Group type: COMPARATOR
Intervention: Receiving 2 or 3 vitamin A supplements in the past 12 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: High baseline total body stores of vitamin A
Number of subjects: 94
Study: 31089967

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy lean volunteers)
Number of subjects: 16
Study: 31090044

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132
Study: 31092022

Group type: EXPERIMENTAL
Intervention: AFEQT questionnaire assessment at baseline and 1 year
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: AFEQT subscale Activities of Daily Living
Number of subjects: 1347

Group type: EXPERIMENTAL
Intervention: AFEQT subscale Symptoms
Number of subjects: 1347
Study: 31092023

Group type: EXPERIMENTAL
Intervention: Revascularization during index hospitalization (70.2% of the cohort)
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Mini-Global Registry of Acute Coronary Events scores at admission
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Longer length of stay
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: In-hospital recurrent angina
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <0.4
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: In-hospital complication
Number of subjects: 3387

Group type: EXPERIMENTAL
Intervention: ST-segment-elevation myocardial infarction
Number of subjects: 3387
Study: 31092170

Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 1328

Group type: EXPERIMENTAL
Intervention: NOAC with clinically relevant anticoagulatory effect
Number of subjects: 1328
Study: 31092203

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 276
Study: 31092478

Group type: EXPERIMENTAL
Intervention: Iatrogenic hyperinsulinemia
Number of subjects: 3

Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 3
Study: 31092592

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride (CPC)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Ethanol (ETOH)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: OMNIgene.SPUTUM (OMNI)
Number of subjects: 133
Study: 31092709

Group type: EXPERIMENTAL
Intervention: Delphi consensus process with 50 patients and 116 health professionals
Number of subjects: 166
Study: 31092713

Group type: EXPERIMENTAL
Intervention: iSLE/iLN
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: iLN
Number of subjects: 216

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 216

Group type: COMPARATOR
Intervention: SLE
Number of subjects: 216
Study: 31092732

Group type: EXPERIMENTAL
Intervention: Highly purified fresh Tregs (91%-96% purity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cryopreserved Tregs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fresh Tregs
Number of subjects: 12
Study: 31093270

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS on the contralesional M1 and anodal tDCS on the ipsilesional M1
Number of subjects: 21
Study: 31093541

Group type: EXPERIMENTAL
Intervention: 14 days clarithromycin
Number of subjects: 4372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study: 31093566

Group type: EXPERIMENTAL
Intervention: SNAP40 wearable monitoring device
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard monitoring devices
Number of subjects: 250
Study: 31093598

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 120
Study: 31093864

Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices) in patients with AUGIB
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Liaoning score (non-invasive prediction score for esophageal varices) in patients without AUGIB
Number of subjects: 363
Study: 31094335

Group type: EXPERIMENTAL
Intervention: Watching the VIA/VILI procedure on a digital screen (IG)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (CG) without watching the procedure
Number of subjects: 118
Study: 31094345

Group type: EXPERIMENTAL
Intervention: Mobile and Web-based complementary and integrative health (CIH) programs
Number of subjects: 456

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 456
Study: 31094744

Group type: EXPERIMENTAL
Intervention: Noradrenaline to increase mean arterial pressure to 85-90 mm Hg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention for mean arterial pressure)
Number of subjects: 40
Study: 31094777

Group type: EXPERIMENTAL
Intervention: Postoperative residual neuromuscular blockade
Number of subjects: 2233
Study: 31094790

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) examination
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Serum albumin level
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: BNP level
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: POCUS abnormalities
Number of subjects: 95
Study: 31094795

Group type: EXPERIMENTAL
Intervention: Pictorial Baxter Retching Faces (BARF) scale
Number of subjects: 192
Study: 31095282

Group type: EXPERIMENTAL
Intervention: Highest egg intake quartile
Number of subjects: 1950

Group type: EXPERIMENTAL
Intervention: Highest cholesterol intake quartile
Number of subjects: 1950
Study: 31095300

Group type: EXPERIMENTAL
Intervention: Predictive model of personalized postprandial glycemic response to foods trained on Israeli cohort meals
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Predictive model of personalized postprandial glycemic response to foods trained on meals from both cohorts
Number of subjects: 327

Group type: COMPARATOR
Intervention: Predictive model considering carbohydrate content
Number of subjects: 327

Group type: COMPARATOR
Intervention: Predictive model considering calorie content
Number of subjects: 327
Study: 31095417

Group type: EXPERIMENTAL
Intervention: Activity modification and load management intervention
Number of subjects: 151